IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab
IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab
复制标题
IgM 抗体相关的多发性神经病：使用利妥昔单抗的 B 细胞耗竭化疗
作者：
T. Levine;A. Pestronk
文章摘要目前抗GM1神经节苷脂或抗髓鞘相关糖蛋白（抗MAG）抗体相关多发性神经病的治疗是有毒的或非常昂贵的。在这项初步研究中，作者通过使用Rituximab（一种针对B细胞表面膜标记物CD 20的单克隆抗体）清除B细胞，治疗了5例神经病和抗GM 1神经节苷脂或MAG的免疫球蛋白M抗体患者。在治疗后3至6个月内，所有5名患者的功能均得到改善，定量强度测量值显著增加，血清自身抗体滴度降低。
Article abstract Current treatments for anti-GM1 ganglioside or antimyelin-associated glycoprotein (anti-MAG) antibody-associated polyneuropathies are toxic or very costly. In this preliminary study the authors treated five patients with neuropathy and immunoglobulin M antibodies to GM1 ganglioside or MAG by depleting B cells using Rituximab—a monoclonal antibody directed against the B-cell surface membrane marker CD20. Within 3 to 6 months after treatment, all five patients had improved function, significantly increased quantitative strength measurements, and reduced titers of serum autoantibodies.
影响因子：
20.3
作者：
ANDERSON, KC;BATES, MP;NADLER, LM
通讯作者：
NADLER, LM